Real-time Quotes | Nasdaq Last Sale

Closed 16:00 11/27 EST
Corp Actions
XBiotech's influenza-COVID-19 therapeutic cocktail shows effective anti-virus activity
XBiotech (XBIT) announces new data for its candidate therapy for treating infections of influenza and COVID-19. The Company continues to analyze components of its FLUVID therapy.The True Human antibodies targeting
Seekingalpha · 11/19 13:56
XBiotech Announces Data Showing Effectiveness Of FLUVID Therapy In COVID-19
AUSTIN, Texas, Nov. 19, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today new data for its breakthrough candidate therapy for treating infections of influenza and COVID-19. The Company continues to
Benzinga · 11/19 13:20
XBiotech Data Shows Effective Anti-Virus Activity for True Human Antibodies in Its Candidate Influenza-COVID-19 Therapeutic Cocktail
Candidate Therapy for Flu+Covid-19 Co-infection Shows Potent Anti-Viral PotentialAUSTIN, Texas, Nov. 19, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today new data for its breakthrough candidate therapy for treating infections of influenza and COVID-19. The Company continues to analyze components of its so-called FLUVID™ therapy as it develops manufacturing capability for a product candidate. The True Human antibodies targeting the virus causing COVID-19 were found to effectively neutralize a test virus at concentrations about four-times better than the antibodies the FDA is now considering for emergency use authorization. Ongoing research has also found that the True Human antibodies in this therapeutic cocktail that target influenza are capable of rescuing 100% of animals that receive an otherwise lethal dose of flu virus. The latest research findings suggest the FLUVID™ therapy, designed to be effective against all known strains of influenza in addition to the COVID-19 virus, could provide a uniquely effective therapy for treating complex infections from one or more of these viruses. There is no other therapy available to treat both COVID-19 and Influenza infections that occur together. With the resurgence of the COVID-19 virus during this oncoming flu season, we are faced with the likelihood that many people will be infected by both influenza and COVID-19 viruses. Co-infections, or “superinfections”, may increase severity of disease and further complicate treatment. A therapy that could treat COVID-19+Influenza co-infections is urgently needed.While the COVID-19 pandemic has only recently emerged, the FLUVID™ candidate therapy is the result of years of Research and Development at XBiotech, incorporating extraordinary influenza True Human antibodies that have been systematically evaluated for their ability to target virtually all known strains of influenza viruses. Whereas the True Human COVID-19 antibodies were derived from patients who recovered rapidly without serious illness and therefore should have potent neutralizing capability against the virus.The influenza strains that will be targeted by FLUVID include: seasonal H1N1 and H3N2 strains; pandemic strains H1N1, H2N2, H3N2; avian influenza strains H5N1, H5N2 and H7N9; and even H9N2 and H10N8, which are currently in poultry but are believed to have pandemic potential in humans.Dr. Sushma Shivaswamy, Ph.D., XBiotech’s Chief Scientific Officer, commented, “We continue to see outstanding data as we move this unique and critical therapy toward the clinic. Unlike any other Research and Development program, our pipeline is focused on delivering therapies to the vulnerable demographic that is most in need of the FLUVID™ therapy. We believe strongly in the potential of this product candidate.”About XBiotech XBiotech is a fully integrated, global biopharmaceutical company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies. XBiotech currently is advancing a pipeline of therapies based on harnessing naturally occurring antibodies from patients with immunity to certain diseases. The approach to use natural human immunity as a source of new medicines offers the potential to redefine the standards of care a wide range of diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative manufacturing technology to reduce the cost and complexity of biological drug production. For more information, visit True Human™ Therapeutic Antibodies XBiotech’s True Human™ antibodies are the only available antibodies derived without modification from humans who possess natural immunity to certain diseases. (Unlike all commercially available antibodies, which are called “Humanized” or “Fully Human”, XBiotech’s True Human™ antibodies are directly sourced from the natural human immune response for specific diseases without modification, and thereby have not been shown to cause immunogenicity.) With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.Contact Ashley Otero 512-386-2930
GlobeNewswire · 11/19 13:15
What Kind Of Shareholders Hold The Majority In XBiotech Inc.'s (NASDAQ:XBIT) Shares?
A look at the shareholders of XBiotech Inc. (NASDAQ:XBIT) can tell us which group is most powerful. Institutions often...
Simply Wall St. · 09/22 20:25
XBiotech Developing True Human Antibody Combination as Candidate Treatment for Influenza-COVID-19 Co-Infections
GlobeNewswire · 09/21 13:20
XBiotech launches new Influenza-COVID-19 antibody test
XBiotech (XBIT) announces the launch of a new breakthrough candidate therapy called FLUVID for treating illness caused by combined infections with influenza and COVID-19.FLUVID therapy will combine XBiotech’s breakthrough influenza True
Seekingalpha · 09/21 12:39
XBiotech Says Is Developing FLUVID For 'treating illness caused by combined infections with influenza and COVID-19'
AUSTIN, Texas, Sept. 21, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today it is developing a new breakthrough candidate therapy it calls FLUVID™ for treating illness caused by combined
Benzinga · 09/21 12:21
Top Biotech Stocks for Q4 2020
These are the biotech stocks with the best value, fastest growth, and most momentum for Q4 2020.
Investopedia · 09/15 20:41
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XBIT. Analyze the recent business situations of XBiotech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts


Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XBIT stock price target is 18.00 with a high estimate of 18.00 and a low estimate of 18.00.
Institutional Holdings
Institutions: 92
Institutional Holdings: 3.97M
% Owned: 13.57%
Shares Outstanding: 29.26M
Sold Out
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Biotechnology & Medical Research
Pharmaceuticals & Medical Research
Key Executives
Chairman/President/Chief Executive Officer/Founder/Director
John Simard
Chief Financial Officer
Scott Whitehurst
Chief Scientific Officer
Sushma Shivaswamy
Vice President - Finance/Director of Human Resources/Secretary
Queena Han
Lead Director/Independent Director
Jan-Paul Waldin
Independent Director
Peter Libby
Independent Director
Donald MacAdam
Independent Director
W. Thorpe McKenzie
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About XBIT
XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system. Xilonix is a therapeutic antibody, which specifically neutralizes interleukin-1 alpha (IL-1a). Its pipeline includes various human antibodies for treating diseases, such as cancer, vascular disease, inflammatory skin disease and diabetes. The Company has completed a Phase III study in Europe for the treatment of symptomatic colorectal cancer. It also investigated its lead product candidate in clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS).
Hot Stocks

Webull offers kinds of XBiotech Inc stock information, including NASDAQ:XBIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XBIT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XBIT stock methods without spending real money on the virtual paper trading platform.